Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

OHR Pharmaceutical Inc (NASDAQ:OHRP)

3.08
Delayed Data
As of 2:01pm ET
 +0.01 / +0.33%
Today’s Change
2.02
Today|||52-Week Range
12.31
-63.07%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$95.8M

Company Description

Ohr Pharmaceutical, Inc. is focused on the development of novel pharmaceuticals for the treatment of serious and unmet medical needs. The company products include Squalamine eye drops for the treatment of the wet form of age-related macular degeneration (wet AMD) with a potential for expansion into other indications such as diabetic macular edema (DME) and retinal vein occlusions (RVO) and OHR/AVR 118 for the treatment of Cancer Cachexia, or wasting syndrome, is characterized by symptoms of loss of appetite and body weight, fatigue, and loss of muscle mass. Ohr Pharmaceutical was founded in 2008 and is headquartered in New York, NY.

Contact Information

Ohr Pharmaceutical, Inc.
800 3rd Avenue
New York New York 10022
P:(212) 682-8452
Investor Relations:

Employees

Shareholders

Mutual fund holders6.33%
Other institutional26.56%
Individual stakeholders19.06%

Top Executives

Irach B. TaraporewalaPresident, Chief Executive Officer & Director
Samuel I. BackenrothChief Financial Officer & VP-Business Development
Glenn StollerChief Scientific Officer
Jason Scott SlakterDirector & Chief Medical Officer
Avner IngermanChief Clinical Officer